c-Jun N-terminal kinase 1/2 (JNK1/2)-mediates PARP-1 phosphorylation and subsequent degradation, while mitogen-activated protein kinase phosphatase-1 (MKP-1) inhibits the activity of JNK1/2 to suppress PARP-1 degradation in cisplatin-resistant ovarian cancer [135]. Here, PARP1 is linked to ovarian cancer.